Under the non-exclusive alliance, Dako and Quintiles will offer integrated drug-diagnostic development services and companion diagnostic products.

As part of the alliance, Dako will develop cancer diagnostic tests and Quintiles will conduct the tests as part of the clinical validation.

Both Dako and Quintiles will continue to work independently with biopharmaceutical companies and service providers in the industry.

Quintiles Global Central Laboratories senior vice president Thomas Wollman said that by pairing core competencies in translational medicine, biomarker discovery and managing clinical trials with Dako’s expertise in companion diagnostics, they can help physician investigators to select the right patients for the right clinical trials, thereby accelerating the development of personalised oncology therapies for customers in the New Health landscape.

Dako CEO Lars Holmkvist said that he was excited about this collaboration and said that this is designed to help biopharma companies streamline the development of safer, more effective targeted therapies.

“By combining highly accurate, reliable diagnostic tests and results with the proper management of critical patient data, we can help companies advance their oncology therapies more rapidly,” Holmkvist said.